SHSE:600566 (China)
Â
Class A
Â¥
41.07
(+2.16%)
Apr 29
Business Description
Hubei Jumpcan Pharmaceutical Co Ltd
NAICS : 333249
ISIN : CNE0000018X6
Share Class Description:
SHSE:600566: Class ACompare
Compare
Traded in other countries / regions
600566.China IPO Date
2001-08-22Description
Hubei Jumpcan Pharmaceutical Co Ltd engages in the research, development, manufacturing, and trading of Chinese traditional medicines, western medicines, daily use chemical based on Chinese traditional medicines, and Chinese medicine health products in China. It offers Chinese and western medicines in the areas of pediatrics, gynecology, pneumology, gastroenterology, and geriatric. The company also develops Chinese and western medicines in the areas of detoxification, digestive system, respiratory system, nervous system, anti-infection, cardiovascular, narcotic analgesic, nutrition, musculoskeletal, and hemostasis.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 7.83 | |||||
| Equity-to-Asset | 0.73 | |||||
| Debt-to-Equity | 0.12 | |||||
| Debt-to-EBITDA | 0.47 | |||||
| Interest Coverage | 133.88 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 6.77 | |||||
| Beneish M-Score | -2.78 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 12.6 | |||||
| 3-Year EBITDA Growth Rate | 22.4 | |||||
| 3-Year EPS without NRI Growth Rate | 25.6 | |||||
| 3-Year FCF Growth Rate | 28.7 | |||||
| 3-Year Book Growth Rate | 18.3 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 27.58 | |||||
| 9-Day RSI | 44.2 | |||||
| 14-Day RSI | 52.02 | |||||
| 6-1 Month Momentum % | 41.3 | |||||
| 12-1 Month Momentum % | 18.64 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.12 | |||||
| Quick Ratio | 3.01 | |||||
| Cash Ratio | 2.59 | |||||
| Days Inventory | 108.23 | |||||
| Days Sales Outstanding | 83.72 | |||||
| Days Payable | 406.11 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 2.15 | |||||
| Dividend Payout Ratio | 0.27 | |||||
| 3-Year Dividend Growth Rate | -10.6 | |||||
| Forward Dividend Yield % | 2.15 | |||||
| 5-Year Yield-on-Cost % | 1.34 | |||||
| 3-Year Average Share Buyback Ratio | -1.2 | |||||
| Shareholder Yield % | 0.88 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 81.3 | |||||
| Operating Margin % | 30.75 | |||||
| Net Margin % | 30.94 | |||||
| FCF Margin % | 32.77 | |||||
| ROE % | 23.4 | |||||
| ROA % | 17.34 | |||||
| ROIC % | 53.35 | |||||
| ROC (Joel Greenblatt) % | 122.24 | |||||
| ROCE % | 27.08 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 12.6 | |||||
| PE Ratio without NRI | 12.72 | |||||
| Shiller PE Ratio | 21.85 | |||||
| Price-to-Owner-Earnings | 14.12 | |||||
| PEG Ratio | 1.65 | |||||
| PS Ratio | 3.9 | |||||
| PB Ratio | 2.67 | |||||
| Price-to-Tangible-Book | 2.76 | |||||
| Price-to-Free-Cash-Flow | 11.9 | |||||
| Price-to-Operating-Cash-Flow | 10.77 | |||||
| EV-to-EBIT | 7.56 | |||||
| EV-to-EBITDA | 7.56 | |||||
| EV-to-Revenue | 2.75 | |||||
| EV-to-FCF | 8.15 | |||||
| Price-to-Projected-FCF | 1.13 | |||||
| Price-to-DCF (Earnings Based) | 0.52 | |||||
| Price-to-DCF (FCF Based) | 0.37 | |||||
| Price-to-Median-PS-Value | 0.98 | |||||
| Price-to-Peter-Lynch-Fair-Value | 1.32 | |||||
| Price-to-Graham-Number | 1.23 | |||||
| Price-to-Net-Current-Asset-Value | 3.61 | |||||
| Price-to-Net-Cash | 4.86 | |||||
| Earnings Yield (Greenblatt) % | 13.23 | |||||
| FCF Yield % | 8.37 | |||||
| Forward Rate of Return (Yacktman) % | 15.61 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Hubei Jumpcan Pharmaceutical Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ¥) | 9,668.786 | ||
| EPS (TTM) (Â¥) | 3.259 | ||
| Beta | 1.22 | ||
| Volatility % | 32.98 | ||
| 14-Day RSI | 52.02 | ||
| 14-Day ATR (Â¥) | 1.354377 | ||
| 20-Day SMA (Â¥) | 40.67 | ||
| 12-1 Month Momentum % | 18.64 | ||
| 52-Week Range (Â¥) | 23.95 - 45.18 | ||
| Shares Outstanding (Mil) | 921.81 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Hubei Jumpcan Pharmaceutical Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Hubei Jumpcan Pharmaceutical Co Ltd Stock Events
| Event | Date | Price(Â¥) | ||
|---|---|---|---|---|
| No Event Data | ||||
Hubei Jumpcan Pharmaceutical Co Ltd Frequently Asked Questions
What is Hubei Jumpcan Pharmaceutical Co Ltd(SHSE:600566)'s stock price today?
The current price of SHSE:600566 is ¥41.07. The 52 week high of SHSE:600566 is ¥45.18 and 52 week low is ¥23.95.
When is next earnings date of Hubei Jumpcan Pharmaceutical Co Ltd(SHSE:600566)?
The next earnings date of Hubei Jumpcan Pharmaceutical Co Ltd(SHSE:600566) is .
Does Hubei Jumpcan Pharmaceutical Co Ltd(SHSE:600566) pay dividends? If so, how much?
The Dividend Yield %  of Hubei Jumpcan Pharmaceutical Co Ltd(SHSE:600566) is 2.15% (As of Today), Highest Dividend Payout Ratio of Hubei Jumpcan Pharmaceutical Co Ltd(SHSE:600566) was 0.83. The lowest was 0.26. And the median was 0.51. The  Forward Dividend Yield % of Hubei Jumpcan Pharmaceutical Co Ltd(SHSE:600566) is 2.15%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers